WHO recommends not using Indian cough syrups linked to Uzbekistan deaths

11 Jan 2023
www.reuters.com
Patent Infringement
Jan 11 (Reuters) - The World Health Organization on Wednesday said that two cough syrups made by India's Marion Biotech should not be used for children, after the products were linked to 19 deaths in Uzbekistan.
Analysis by Uzbekistan's health ministry showed the syrups, Ambronol and DOK-1 Max, contained a toxic substance, ethylene glycol. The syrups were administered in doses higher than the standard for children, either by their parents, who mistook it for an anti-cold remedy, or on the advice of pharmacists, according to the analysis.
So far, Marion has not provided guarantees to WHO on the safety and quality of these products, the agency said. Shortly after the series of deaths were reported in Uzbekistan, India's health ministry suspended production at the company. According to a recent report, India's Uttar Pradesh state has suspended Marion's production license.
Marion did not immediately respond to a Reuters request for comment. Last week, the Uzbek state security service arrested four people in an investigation into the cough-syrup related deaths of 19 children.
The Uzbekistan case follows deaths of at least 70 children in Gambia that a parliamentary committee had linked to cough and cold syrups manufactured by New Delhi-based Maiden Pharmaceuticals. The company denied any wrongdoing and Indian government inspectors found no contamination in test samples.
Our Standards: The Thomson Reuters Trust Principles.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.